Participated · Series B · Jan 2026

Vista AI provides an AI-driven cardiac MRI automation platform that allows technologists of any experience level to consistently acquire high-quality scans. Its software, already FDA-cleared and commercially deployed, has enabled hospitals such as Brigham and Women’s to open 50 % more scan slots and eliminate a 28-day backlog, while cutting scan times by more than 50 % at Radiology Regional. Headquartered in Palo Alto, the company plans to extend its technology to brain, prostate, and spine imaging, pending additional FDA clearances, and to offer remote scanning services so facilities without in-house experts can perform advanced MRI exams. These expansions aim to create the first comprehensive, fully automated MRI platform and to mitigate the industry’s acute technologist shortage. Vista AI is backed by leading venture funds and prominent U.S. health systems. Following its latest raise, the firm intends to accelerate product development, broaden clinical adoption, and deepen its presence across health networks. The company’s momentum underscores strong demand for solutions that standardize imaging quality while expanding patient access.

Participated · Series A · Sep 2024

Segmed provides real-world medical imaging data to life-sciences, health care and technology firms via a proprietary platform that acquires, de-identifies, standardizes, and delivers imaging studies. The company supports biopharmaceutical R&D, AI/ML development and real-world imaging data (RWiD) use cases. Segmed partners with health-care locations and imaging clinics across five continents to source the studies researchers and developers need. Led by CEO Martin Willemink, the company intends to use the Series A proceeds to further expand its medical imaging solutions for AI development and real-world evidence. Financially, Segmed raised $10.4M in a Series A and previously received financing from Flashpoint Growth Debt Fund in 2023. The company is headquartered in Palo Alto, California. Segmed offers a cloud-based real-world imaging platform, Segmed Insight, that enables medical researchers and AI developers to search, view studies and reports matching their criteria, and construct custom datasets. After placing an order users receive data in hand within days. The company has signed partnerships with healthcare systems, hospitals and imaging clinics across 1,000 locations on five continents. Led by CEO Martin Willemink, Segmed is based in Palo Alto, California. It raised $5.2M in a Seed+ round and has now raised more than $10M to date. The company intends to use the funds to accelerate growth, expand operations and broaden its business reach. Segmed is a secure, cloud-based platform that curates medical data by anonymizing, standardizing and labeling it to accelerate innovation in healthcare. Led by co-founder and CEO Cailin Hardell, the company partners with diverse healthcare providers around the world to source data. It standardizes and indexes medical data via a sequence of proprietary algorithms and enables customers to build customized datasets. Segmed positions itself as a shop for rapid, low-cost data aggregation and standardization for medical AI development. The company maintains strict HIPAA compliance and only uses and shares data that is fully anonymized. Financially, Segmed closed a $2M seed funding round in March 2020 to support its platform.

Participated · Series B · Jun 2022

Elucid's core product, PlaqueIQ, is an AI-powered computed tomography angiography (CTA) analysis software that objectively quantifies and characterizes arterial plaque and is FDA-cleared. The software simulates histology and is validated against tens of thousands of tissue annotations by pathologists. Elucid is pursuing an additional indication for non-invasive fractional flow reserve measurement (FFRCT) uniquely derived from its PlaqueIQ technology. The plaque analysis software is commercially available in the U.S., UK, EU, and South Korea. The company has been ramping commercial efforts, expanding clinical research and development, and has significantly bolstered its leadership team. Financially, Elucid announced an $80 million Series C and has raised $121 million in total funding since inception. Elucid builds interpretable, validated AI software that non-invasively quantifies atherosclerotic plaque characteristics compared to histopathology, including lipid rich necrotic core. Its machine-learning algorithms characterize tissue types in the artery wall and power applications that derive FFRct, estimate risk of heart attack/stroke, and produce expression-prediction outputs to inform therapeutic selection. The platform enables physicians to diagnose causes of chest pain and detect early-stage heart disease not visible with alternative methods. The software is FDA-cleared and CE-marked and is commercially available in the U.S., Europe, and South Korea. Led by CEO Blake Richards, the company intends to use new funding to accelerate growth and further development efforts. No revenue or user metrics were reported in the article. Elucid develops interpretable, validated AI software (ElucidVivo) to help physicians detect cardiovascular disease and optimize treatment decisions. ElucidVivo is the first FDA-cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics versus histopathology, including lipid-rich necrotic core, and is commercially available in the U.S. and Europe. The company has published studies on deriving fractional flow reserve (FFRct) from vasodilative vessel-wall capacity and on estimating coding and non-coding RNA transcripts (“Virtual Transcriptomics”). Management says the technology aims to reduce invasive procedures, improve diagnostic power, and enable precision medicine for cardiac and neurovascular patients. Recent hires include Jason Bottiglieri as Chief Commercial Officer and Murali Ayyapillai as Vice President of Engineering to support commercialization and product development. The company plans to continue advancing and commercializing its platform to improve outcomes and reduce healthcare costs.